IPP-204106

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameIPP-204106
Drug Alias NameNucant programme IPP-204106polyplexed NucantIPP-204106IPP-204106NNucant-6L +[7
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionNucleolin inhibitors
TargetsNucleolin
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmupharma Plc
China Registration ClassN/A

Develop Information

Active CompaniesImmupharma Plc
Inactive CompaniesElro Pharma
Active IndicationsNeoplasms
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A